Enhanced-affinity murine T-cell receptors for tumor/self-antigens can be safe in gene therapy despite surpassing the threshold for thymic selection

Blood

Volumn 122, Issue 3, 2013, Pages 348-356

  Schmitt, Thomas M ^a   Aggen, David H ^b   Stromnes, Ingunn M ^a   Dossett, Michelle L ^c   Richman, Sarah A ^d   Kranz, David M ^b   Greenberg, Philip D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; RETROVIRUS VECTOR; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; WT1 PROTEIN; AUTOANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR; MUTANT PROTEIN;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; CANCER GENE THERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CELL LINEAGE; CELL SELECTION; CONTROLLED STUDY; ENGRAFTMENT; IMMUNOLOGICAL TOLERANCE; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE; TARGET CELL; THYMUS; VIRAL GENE THERAPY; ANIMAL; C57BL MOUSE; GENE THERAPY; GENETIC TRANSDUCTION; HUMAN; IMMUNOLOGY; LISTERIA MONOCYTOGENES;

ANIMALS; ANTIGENS, NEOPLASM; AUTOANTIGENS; GENETIC THERAPY; HUMANS; LISTERIA MONOCYTOGENES; MICE; MICE, INBRED C57BL; MUTANT PROTEINS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES; THYMUS GLAND; TRANSDUCTION, GENETIC;

EID: 84883704931     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-01-478164     Document Type: Article

References (43)

1. Schmitt TM, Ragnarsson GB, Greenberg PD. T cell receptor gene therapy for cancer. Hum Gene Ther. 2009;20(11):1240-1248.
2. Falkenburg WJJW, Melenhorst JJJ, van de Meent MM, et al. Allogeneic HLA-A∗02-restricted WT1-specific T cells from mismatched donors are highly reactive but show off-target promiscuity. J Immunol. 2011;187(5):2824-2833.
3. Chervin AS, Aggen DH, Raseman JM, Kranz DM. Engineering higher affinity T cell receptors using a T cell display system. J Immunol Methods. 2008;339(2):175-184.
4. Robbins PF, Li YF, El-Gamil M, et al. Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J Immunol. 2008;180(9):6116-6131.
5. Li Y, Moysey R, Molloy PE, et al. Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nat Biotechnol. 2005; 23(3):349-354.
6. Ariyaratana S, Loeb DM. The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesis. Expert Rev Mol Med. 2007; 9(14):1-17.
7. Scharnhorst V, van der Eb AJ, Jochemsen AG. WT1 proteins: functions in growth and differentiation. Gene. 2001;273(2):141-161.
8. Simpson AJG, Caballero OL, Jungbluth A, Chen Y-T, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer. 2005;5(8):615-625.
9. Holst J, Vignali KM, Burton AR, Vignali DA. Rapid analysis of T-cell selection in vivo using T cellreceptor retrogenic mice. Nat Methods. 2006;3(3): 191-197.
10. Pui JC, Allman D, Xu L, et al. Notch1 expression in early lymphopoiesis influences B versus T lineage determination. Immunity. 1999;11(3): 299-308.
11. Letourneur F, Malissen B. Derivation of a T cell hybridoma variant deprived of functional T cell receptor a and b chain transcripts reveals a nonfunctional a-mRNA of BW5147 origin. Eur J Immunol. 1989;19(12):2269-2274.
12. Chervin AS, Stone JD, Holler PD, Bai A, Chen J, Eisen HN, Kranz DM. The impact of TCR-binding properties and antigen presentation format on T cell responsiveness. J Immunol. 2009;183(2): 1166-1178.
13. Holler PD, Kranz DM. Quantitative analysis of the contribution of TCR/pepMHC affinity and CD8 to T cell activation. Immunity. 2003;18(2):255-264.
14. Stone JD, Chervin AS, Kranz DM. T-cell receptor binding affinities and kinetics: impact on T-cell activity and specificity. Immunology. 2009;126(2): 165-176.
15. Daniels MA, Jameson SC. Critical role for CD8 in T cell receptor binding and activation by peptide/ major histocompatibility complex multimers. J Exp Med. 2000;191(2):335-346.
16. Inoue K, Ogawa H, Sonoda Y, et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood. 1997;89(4):1405-1412.
17. Spangrude GJ, Heimfeld S, Weissman IL. Purification and characterization of mouse hematopoietic stem cells. Science. 1988; 241(4861):58-62.
18. Azzam HS, Grinberg A, Lui K, Shen H, Shores EW, Love PE. CD5 expression is developmentally regulated by T cell receptor (TCR) signals and TCR avidity. J Exp Med. 1998;188(12): 2301-2311.
19. Terrence K, Pavlovich CP, Matechak EO, Fowlkes BJ. Premature expression of T cell receptor (TCR)alphabeta suppresses TCRgammadelta gene rearrangement but permits development of gammadelta lineage T cells. J Exp Med. 2000;192(4):537-548.
20. Egawa T, Kreslavsky T, Littman DR, von Boehmer H. Lineage diversion of T cell receptor transgenic thymocytes revealed by lineage fate mapping. PLoS ONE. 2008;3(1):e1512.
21. Cheever MA, Allison JP, Ferris AS, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009; 15(17):5323-5337.
22. Schmid DA, Irving MB, Posevitz V, et al. Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function. J Immunol. 2010;184(9): 4936-4946.
23. Johnson LA, Heemskerk B, Powell DJ Jr, et al. Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumorinfiltrating lymphocytes. J Immunol. 2006;177(9): 6548-6559.
24. Zhao Y, Bennett AD, Zheng Z, et al. High-affinity TCRs generated by phage display provide CD41 T cells with the ability to recognize and kill tumor cell lines. J Immunol. 2007;179(9):5845-5854.
25. Holler PD, Holman PO, Shusta EV, O'Herrin S, Wittrup KD, Kranz DM. In vitro evolution of a T cell receptor with high affinity for peptide/MHC. Proc Natl Acad Sci USA. 2000;97(10):5387-5392.
26. Park S, Schalling M, Bernard A, et al. The Wilms tumour gene WT1 is expressed in murine mesoderm-derived tissues and mutated in a human mesothelioma. Nat Genet. 1993;4(4): 415-420.
27. Lee SB, Haber DA. Wilms tumor and the WT1 gene. Exp Cell Res. 2001;264(1):74-99.
28. Zehn D, Bevan MJ. T cells with low avidity for a tissue-restricted antigen routinely evade central and peripheral tolerance and cause autoimmunity. Immunity. 2006;25(2):261-270.
29. Oldstone MB, Nerenberg M, Southern P, Price J, Lewicki H. Virus infection triggers insulindependent diabetes mellitus in a transgenic model: role of anti-self (virus) immune response. Cell. 1991;65(2):319-331.
30. Ohashi PS, Oehen S, Buerki K, et al. Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell. 1991;65(2):305-317.
31. Gaiger A, Reese V, Disis ML, Cheever MA. Immunity to WT1 in the animal model and in patients with acute myeloid leukemia. Blood. 2000;96(4):1480-1489.
32. Oka Y, Udaka K, Tsuboi A, et al. Cancer immunotherapy targeting Wilms' tumor gene WT1 product. J Immunol. 2000;164(4):1873-1880.
33. Gao L, Xue SA, Hasserjian R, et al. Human cytotoxic T lymphocytes specific for Wilms' tumor antigen-1 inhibit engraftment of leukemia-initiating stem cells in non-obese diabetic-severe combined immunodeficient recipients. Transplantation. 2003;75(9):1429-1436.
34. Pospori C, Xue S-A, Holler A, et al. Specificity for the tumor-associated self-antigen WT1 drives the development of fully functional memory T cells in the absence of vaccination. Blood. 2011; 117(25):6813-6824.
35. Rudolph MG, Stanfield RL, Wilson IA. How TCRs bind MHCs, peptides, and coreceptors. Annu Rev Immunol. 2006;24:419-466.
36. Alli R, Nguyen P, Geiger TL. Retrogenic modeling of experimental allergic encephalomyelitis associates T cell frequency but not TCR functional affinity with pathogenicity. J Immunol. 2008;181(1):136-145.
37. Burton AR, Vincent E, Arnold PY, et al. On the pathogenicity of autoantigen-specific T-cell receptors. Diabetes. 2008;57(5):1321-1330.
38. Goldrath AW, Bevan MJ. Low-affinity ligands for the TCR drive proliferation of mature CD81 T cells in lymphopenic hosts. Immunity. 1999; 11(2):183-190.
39. Ernst B, Lee DS, Chang JM, Sprent J, Surh CD. The peptide ligands mediating positive selection in the thymus control T cell survival and homeostatic proliferation in the periphery. Immunity. 1999;11(2):173-181.
40. Viret C, Wong FS, Janeway CA Jr. Designing and maintaining the mature TCR repertoire: the continuum of self-peptide:self-MHC complex recognition. Immunity. 1999;10(5): 559-568.
41. Ohlén C, Kalos M, Cheng LE, et al. CD8(1) T cell tolerance to a tumor-associated antigen is maintained at the level of expansion rather than effector function. J Exp Med. 2002;195(11): 1407-1418.
42. Kisielow P, Bl üthmann H, Staerz UD, Steinmetz M, von Boehmer H. Tolerance in T-cell-receptor transgenic mice involves deletion of nonmature CD4181 thymocytes. Nature. 1988;333(6175): 742-746.
43. Soto CM, Stone JD, Chervin AS, Engels B, Schreiber H, Roy EJ, Kranz DM. MHC-class I-restricted CD4 T cells: a nanomolar affinity TCR has improved anti-tumor efficacy in vivo compared to the micromolar wild-type TCR. Cancer Immunol Immunother. 2013;62(2): 359-369.